ADMA Biologics (NASDAQ:ADMA) Rating Lowered to “Strong Sell” at Zacks Research

ADMA Biologics (NASDAQ:ADMA) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Tuesday,Zacks.com reports.

A number of other analysts have also weighed in on ADMA. Canaccord Genuity Group lowered their target price on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Raymond James Financial began coverage on shares of ADMA Biologics in a research report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 price target on the stock. Mizuho lowered their price objective on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $18.67.

ADMA Biologics Price Performance

NASDAQ:ADMA opened at $9.26 on Tuesday. The company has a quick ratio of 3.93, a current ratio of 6.95 and a debt-to-equity ratio of 0.51. The firm has a market cap of $2.15 billion, a PE ratio of 13.62 and a beta of 0.74. ADMA Biologics has a 12 month low of $7.21 and a 12 month high of $20.46. The company’s 50-day moving average price is $8.55 and its two-hundred day moving average price is $11.37.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16. The company had revenue of $124.39 million during the quarter, compared to analysts’ expectations of $125.34 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. ADMA Biologics’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.14 earnings per share. On average, equities analysts anticipate that ADMA Biologics will post 0.8 EPS for the current fiscal year.

Insider Transactions at ADMA Biologics

In other news, Director Jerrold B. Grossman purchased 12,500 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average price of $8.01 per share, for a total transaction of $100,125.00. Following the completion of the acquisition, the director directly owned 513,884 shares in the company, valued at approximately $4,116,210.84. The trade was a 2.49% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 3.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Summit Securities Group LLC bought a new position in shares of ADMA Biologics in the 4th quarter valued at about $29,000. Western Wealth Management LLC acquired a new position in ADMA Biologics in the first quarter valued at approximately $31,000. iSAM Funds UK Ltd bought a new position in ADMA Biologics in the third quarter valued at approximately $34,000. Optima Capital LLC bought a new stake in shares of ADMA Biologics during the 4th quarter valued at $36,000. Finally, Morse Asset Management Inc acquired a new position in shares of ADMA Biologics in the 4th quarter valued at $44,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: ADMA reported second-quarter revenue of $124.4 million, up 2% year over year, while GAAP net income rose 11% to $37.8 million. Adjusted EBITDA increased 22% to $61.8 million, supporting the company’s profitability profile. ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Quarterly EPS met the $0.16 analyst consensus, and ASCENIV revenue climbed 24% to $102.9 million. Management also said BIVIGAM demand and revenue stabilized sequentially, indicating improving utilization trends. ADMA Biologics Q2 Earnings Snapshot
• Positive Sentiment: The company reiterated 2026 revenue guidance of $530 million to $560 million, broadly consistent with the $534.9 million consensus estimate, and is targeting more than $200 million in share repurchases. Buybacks could provide demand for the stock and increase per-share value if executed. ADMA Reiterates 2026 Guidance and Targets Share Repurchases
• Neutral Sentiment: Management highlighted new real-world evidence on ASCENIV’s patient outcomes and healthcare-resource utilization, potentially supporting longer-term demand, although the evidence remains an upcoming catalyst rather than a reported financial result.
• Negative Sentiment: Multiple law firms are promoting a securities-fraud class action covering investors who purchased ADMA securities from August 9, 2024, through March 25, 2026. The complaints allege misleading statements involving revenue, financial condition, inventory distribution and business practices. Lead-plaintiff notices cite an August 10 deadline. The allegations have not been proven, but the litigation creates legal costs, reputational risk and potential financial exposure. ADMA Securities Fraud Lawsuit Notice

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.